Longeveron Inc.
LGVN Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.60
KIRA · Stoqly’s AI analyst, in plain words
- Longeveron Inc. had $1.2M of revenue in fiscal 2025, down 49.9% on the year before. Over five years, revenue changed −26.6% a year on average.
- Its operating margin was −1,942.2%, down 1,251.5 pts: of every 100 in sales, about −1,942 is left after running the business.
- Longeveron Inc. lost $22.7M in fiscal 2025.
- Free cash flow was −$18.9M in fiscal 2025, −1,575.5% of revenue.
Market cap
$50.2M
P/E
—
Revenue
$1.2M
Net income
−$22.7M
Free cash flow
−$18.9M
Operating margin
−1,942.2%
Longeveron Inc. in 30 seconds · fiscal 2025
Are sales growing?
−49.9%
No. Sales fell 49.9% last year.
Does it make a profit?
−1,893.6%
No. It lost money last year.
Does profit turn into cash?
−1,575.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Longeveron Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- Longeveron Inc.
- CIK
- 0001721484
Longeveron Inc. · LGVN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.3M | $1.2M | $0.7M | $2.4M | $1.2M |
| Revenue growth | −76.8% | −6.4% | −42.0% | 237.4% | −49.9% |
| Gross margin | 45.2% | 40.7% | 31.2% | 78.8% | 67.0% |
| Operating margin | −1,336.6% | −1,476.5% | −2,966.0% | −690.7% | −1,942.2% |
| Net income | −$17.0M | −$18.8M | −$21.4M | −$16.0M | −$22.7M |
| Net margin | −1,305.1% | −1,541.3% | −3,020.2% | −667.8% | −1,893.6% |
| Diluted EPS | −$0.90 | −$0.90 | −$10.22 | −$2.62 | −$1.29 |
| Cash | |||||
| Cash from operations | −$9.6M | −$14.0M | −$19.0M | −$13.9M | −$18.6M |
| Capital expenditure | $0.3M | $0.6M | $0.3M | $0.7M | $0.2M |
| Free cash flow | −$10.0M | −$14.5M | −$19.3M | −$14.5M | −$18.9M |
| FCF margin | −763.1% | −1,189.7% | −2,722.6% | −607.1% | −1,575.5% |
| Share count change | 18.0% | 10.9% | 10,265.3% | 333.0% | 86.8% |
| Debt and strength | |||||
| Cash and short-term investments | $35.1M | $19.7M | $5.4M | $19.2M | $4.7M |
| Shareholders' equity | $37.5M | $20.5M | $6.7M | $21.9M | $5.7M |
| Current ratio | 13.1x | 4.2x | 1.5x | 7.6x | 1.3x |
| Interest coverage | −4,364.0x | −12.9x | — | — | — |
| Returns and quality | |||||
| Return on equity | −86.5% | −65.0% | −157.2% | −111.6% | −164.7% |
| Return on tangible equity | −48.5% | −104.1% | −498.7% | −126.4% | −669.7% |
| Piotroski F-score | 4 | 2 | 2 | 5 | 2 |
| Altman Z'' | 6.3 | −5.1 | −32.2 | −7.7 | −55.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Longeveron Inc. · LGVN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.60 a share, the company is worth $50.2M.
Source: SEC EDGAR XBRL filings (CIK 0001721484). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.